Beyond approval: Patients pursue alternate paths to get rare disease treatments
As post-approval boundaries disproportionately affect rare disease patients, communities are rallying behind alternative options.
29 February 2024
29 February 2024
As post-approval boundaries disproportionately affect rare disease patients, communities are rallying behind alternative options.
Biotechs need to navigate US-China relations when pursuing collaborations and drug manufacturing partnerships.
The guidance introduces a technical completeness check to ensure the submission contains all necessary data.
IRA regulations have changed how pharma is approaching innovation in cancer drug discovery and development.
Making therapies feasible from biological, regulatory, and commercial standpoints drives scalable genetic medicine.
The industry must utilise AI with the mindset to innovate over the desire to slash drug costs and reduce time to commercialisation.
The Phase III VELA programme will compare the IL-17 inhibitor sonelokimab to a placebo, enrolling 800 patients over 52 weeks.
AbbVie will pay $48m in upfront costs and up to $665m in milestone payments to license OSE’s monoclonal antibody OSE-230.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.